In a nutshell This study evaluated the safety and effectiveness of the BR (bendamustine, rituximab) regimen as a second-line treatment for patients with follicular lymphoma (FL) who had disease progression (tumor growth or spread) after chemoimmunotherapy. The study concluded that this regimen was effective in these patients. Some background...
Read MoreType(s) of biological therapy-Rituximab Posts on Medivizor
Evaluating the impact of adding combination antiretroviral therapy to chemotherapy in HIV-positive patients with non-Hodgkin’s lymphoma
In a nutshell This study evaluated the outcomes of concurrent (at the same time) combination antiretroviral therapy (cART) and chemotherapy in HIV-positive patients with non-Hodgkin’s lymphoma (NHL). This study concluded that concurrent cART with chemotherapy was well-tolerated and allowed for faster immune recovery in these patients, but did not...
Read MoreEvaluating rituximab maintenance therapy in patients with newly diagnosed follicular lymphoma
In a nutshell This study evaluated the effectiveness of rituximab (Rituxan) maintenance therapy in patients with newly diagnosed follicular lymphoma (FL). This study concluded that this therapy improves survival outcomes in these patients. Some background For patients with early (stage 1 – 2) FL, aggressive radiotherapy or...
Read MoreEvaluating the impact of omitting vincristine on the outcomes of patients with DLBCL
In a nutshell This study investigated whether the omission of vincristine (Oncovin) from the R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) regimen affects survival in patients with diffuse large B-cell lymphoma (DLBCL). This study concluded that omitting vincristine does not affect survival in these patients. Some background...
Read MoreEvaluating the BR regimen for frail elderly patients with DLBCL
In a nutshell This study evaluated the safety and effectiveness of first-line (primary treatment) BR (bendamustine, rituximab) in frail elderly patients with diffuse large B-cell lymphoma (DLBCL). This study concluded that the BR treatment showed promising effectiveness in these patients. Some background DLBCL is the most common type of...
Read MorePredicting outcomes for patients with DLBCL using the albumin to globulin ratio
In a nutshell This study evaluated the significance of the albumin to globulin ratio in pretreated patients with diffuse large B-cell lymphoma. The study concluded that this ratio was useful for predicting treatment outcomes in these patients. Some background R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) is the most...
Read MoreIs pirarubicin safer and more effective than doxorubicin in R-CHOP for diffuse large B-cell lymphoma?
In a nutshell This study compared the safety and effectiveness of two first-line chemotherapy regimens for diffuse large B-cell lymphoma. This study concluded that the R-THP-COP regimen was as effective as conventional R-CHOP for diffuse large B-cell lymphoma. Some background R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine,...
Read MoreChemotherapy after radiotherapy for early-stage follicular lymphoma
In a nutshell This study investigated the safety and effectiveness of systemic chemotherapy after radiotherapy for early-stage follicular lymphoma. This study concluded that this combined treatment is more effective than radiotherapy alone for early-stage follicular lymphoma. Some background Radiotherapy can help control local disease in more than 90%...
Read MoreCombined ibrutinib and venetoclax for mantle cell lymphoma
In a nutshell This study investigated the safety and effectiveness of ibrutinib (Imbruvica) plus venetoclax (Venclexta) for the treatment of mantle cell lymphoma. This study concluded that this regimen improved outcomes in patients with mantle cell lymphoma. Some background The standard treatment for mantle cell lymphoma (MCL)...
Read MoreDoes 8 cycles of R-CHOP lead to better survival than 6 cycles for diffuse large B-cell lymphoma?
In a nutshell This study examined whether 6 or 8 cycles of R-CHOP-21 (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy led to better survival outcomes in patients with newly diagnosed diffuse large B-cell lymphoma. This study concluded that outcomes following 6 or 8 cycles of R-CHOP-21 are similar for these patients. Some...
Read MoreMOR208: a new antibody therapy for relapsed or refractory non-Hodgkin’s lymphoma
In a nutshell This study investigated the safety and effectiveness of MOR208 in patients with relapsed or refractory (does not respond to treatment) non-Hodgkin’s lymphoma. This study concluded that MOR208 monotherapy was safe and showed promising results in these patients. Some background Chemoimmunotherapy is the current standard first-line...
Read MoreReviewing radiation therapy options for patients with relapsed or persistent DLBCL
In a nutshell This study reviewed several studies involving patients with relapsed or refractory (does not respond to treatment) diffuse large B-cell lymphoma (DLBCL) who received radiation therapy (RT). The authors concluded that RT can improve outcomes and disease control for patients with localized disease. Some background Diffuse large B-cell...
Read More